Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma

Jennifer J. Gile, Vanessa Wookey, Tyler J. Zemla, Qian Shi, Zhaohui Jin, Steven R. Alberts, Robert R. McWilliams, Wen Wee Ma, Mitesh Borad, Tanios S. Bekaii-Saab, Nguyen H. Tran, Amit Mahipal

Research output: Contribution to journalArticlepeer-review


Background: Sequencing efforts in patients with cholangiocarcinoma (CCA) have provided insights into molecular mechanisms including fibroblast growth factor receptor (FGFR) alterations. There is a lack of data on outcomes of patients following cessation of FGFR inhibitor (FGFRi) therapy. Objective: We describe the clinical outcomes following initial FGFRi treatment in CCA harboring FGFR alterations. Patients and methods: We conducted a multicentric, retrospective analysis of patients with FGFR-altered CCA diagnosed between 2010 and 2021. Median overall survival (OS) and progression-free survival (PFS) analyses were performed using the Kaplan-Meier method. Results: We identified 88 advanced or metastatic CCA patients, 28 males (31.8%) and 60 females (68.2%), harboring FGFR alterations who received FGFRi. Median PFS on initial FGFRi was 6.6 months (95% confidence interval (CI): 5.5–8.3). Following cessation of first FGFRi therapy, 55% patients received systemic therapy as next line: 67% received chemotherapy or targeted treatment and 33% received another FGFRi. Median PFS for patients who received chemotherapy or targeted agent was 2.1 months (95% CI 1.6–5.7) and for patients who received a second FGFRi was 3.7 months (95% CI 1.5–not evaluable). OS was 2.0 months for patients who did not receive any therapy compared to 8.7 months with chemotherapy and 8.6 months with another FGFRi. In addition, one patient treated with pemigatinib developed FGFR2 M540_I541insMM alteration at time of resistance, which has not been functionally characterized and its effect on protein function remains unknown. Conclusions: Understanding the mechanisms of resistance with FGFRi is essential to understand sequencing of treatments. In this study, patients received standard chemotherapy in the first line and were fit enough to be considered for subsequent therapy with an FGFRi. Almost half of the patients become ineligible to receive further systemic therapy following progression on FGFRi. As more agents are being introduced, detailed understanding of outcomes following treatment with an FGFRi, including subsequent FGFRi, is essential.

Original languageEnglish (US)
Pages (from-to)529-538
Number of pages10
JournalTargeted Oncology
Issue number5
StatePublished - Sep 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this